{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:06:14Z","timestamp":1789578374626,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2025.12.016","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:47:36Z","timestamp":1769093256000},"page":"777-785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective Study"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1852-5881","authenticated-orcid":false,"given":"Garvey","family":"Mezepo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-789X","authenticated-orcid":false,"given":"Zine-Eddine","family":"Khene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihane","family":"Boustani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Kleinclauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Quivrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Neftah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sophie","family":"Bajeot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Mardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Hammoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Bouvier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Jacquey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loic","family":"Choffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Palkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Benyoucef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carroline","family":"Brassart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauthier","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazim","family":"Khalladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Coutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Huck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Roumiguie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.12.016_b0005","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.016_b0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.016_b0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.016_b0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","article-title":"Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology","volume":"55","author":"Shabsigh","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.016_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2021.03.010","article-title":"Morbidity and days alive and out of hospital within 90 days following radical cystectomy for bladder cancer","volume":"28","author":"Maibom","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2025.12.016_b0030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2025.03.017","article-title":"Bladder preservation strategies in muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"89","author":"Gupta","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.016_b0035","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2017.03.038","article-title":"Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder","volume":"72","author":"Seisen","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.016_b0040","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.12.016_b0045","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic differences between \u201cprimary\u201d and \u201csecondary\u201d muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.016_b0050","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.euros.2022.05.001","article-title":"The impact of primary versus secondary muscle-invasive bladder cancer at diagnosis on the response to neoadjuvant chemotherapy","volume":"41","author":"D\u2019Andrea","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2025.12.016_b0055","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euros.2022.02.011","article-title":"Comparative outcomes of primary versus recurrent high-risk non\u2013muscle-invasive and primary versus secondary muscle-invasive bladder cancer after radical cystectomy: results from a retrospective multicenter study","volume":"39","author":"Grossmann","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2025.12.016_b0060","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.016_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2021.05.009","article-title":"Outcomes for muscle-invasive bladder cancer with radical cystectomy or trimodal therapy in US Veterans","volume":"30","author":"Kumar","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2025.12.016_b0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.euros.2022.02.010","article-title":"A multicenter retrospective cohort series of muscle-invasive bladder cancer patients treated with definitive concurrent chemoradiotherapy in daily practice","volume":"39","author":"de Ruiter","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2025.12.016_b0075","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.016_b0080","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.eururo.2020.11.036","article-title":"Outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy followed by (chemo)radiotherapy in the BC2001 trial","volume":"79","author":"Hussain","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.016_b0085","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.euo.2024.01.014","article-title":"Benefit of neoadjuvant cisplatin-based chemotherapy for invasive bladder cancer patients treated with radiation-based therapy in a real-world setting: an inverse probability treatment weighted analysis","volume":"7","author":"Kool","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.12.016_b0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.euo.2023.02.008","article-title":"A systematic review of oncological outcomes associated with bladder-sparing strategies in patients achieving complete clinical response to initial systemic treatment for localized muscle-invasive bladder cancer","volume":"6","author":"Grobet-Jeandin","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.12.016_b0095","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.23.02510","article-title":"Bladder preserving trimodality treatment for high-grade T1 bladder cancer: results from phase II protocol NRG Oncology\/RTOG 0926","volume":"42","author":"Dahl","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.12.016_b0100","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.12.016_b0105","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.euo.2025.05.028","article-title":"Radiation therapy in the management of muscle-invasive bladder cancer with carcinoma in situ: still a no go?","volume":"8","author":"Huck","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.12.016_b0110","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.euo.2023.03.004","article-title":"Radiation-based therapy for muscle-invasive bladder cancer: contemporary outcomes across tertiary centers","volume":"6","author":"Kool","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.12.016_b0115","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.euros.2021.11.011","article-title":"Role of serum lymphocyte-derived biomarkers in nonmetastatic muscle-invasive bladder cancer patients treated with trimodal therapy","volume":"36","author":"Kool","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2025.12.016_b0120","article-title":"New insights and emerging approaches in bladder-sparing treatment for muscle-invasive bladder cancer","volume":"49","author":"Subiela","year":"2025","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"10.1016\/j.euo.2025.12.016_b0125","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euros.2022.06.009","article-title":"Impact of programmed death-ligand 1 expression on oncological outcomes in patients with muscle-invasive bladder cancer treated with radiation-based therapy","volume":"43","author":"Marcq","year":"2022","journal-title":"Eur Urol Open Sci"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125003438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125003438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:46:40Z","timestamp":1789577200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125003438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2588931125003438"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.12.016","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}